Understanding Type B Insulin Resistance Syndrome

Receiving a diagnosis of Type B Insulin Resistance Syndrome (TBIRS) can be overwhelming and frightening. You may find yourself taking doses of insulin that seem impossible—hundreds or even thousands of units a day—while your blood sugar remains stubbornly high. This experience is vastly different from the typical management of Type 1 or Type 2 diabetes, and it is normal to feel confused by the scale of the treatment ^[1][2].

The most important thing to understand is that your body is not simply “resistant” to insulin in the way a person with Type 2 diabetes might be. Instead, your immune system has mistakenly created autoantibodies (proteins that usually fight germs) that are specifically attacking and blocking your insulin receptors (the “locks” on your cells that insulin needs to open to let sugar in) ^[3][4]. Because these receptors are physically blocked by your own immune system, the insulin you inject cannot find a place to work, necessitating massive doses just to force a small amount of sugar into your cells ^[5][1].

Three Stabilizing Facts

While the diagnosis is rare and serious, three key facts provide a foundation for your care:

1. It is an autoimmune disease, not standard diabetes. Unlike Type 2 diabetes, which is a metabolic condition, TBIRS is an immune system error. It is often found alongside other autoimmune conditions like Systemic Lupus Erythematosus (SLE) ^[6][7].
2. It is potentially curable. Research has identified specific protocols, most notably the NIH protocol (developed at the National Institutes of Health), which uses targeted medications to stop the production of the offending antibodies ^[8][9].
3. The outlook has changed significantly. You may find older medical texts citing a mortality rate of 54%. This is outdated information. With modern immunosuppressive treatments, the condition is now considered potentially curable, with many patients achieving complete remission ^[9][7].

How the Treatment Works

Because the root cause is your immune system, the primary treatment is not just “more insulin,” but rather immunomodulatory therapy. The goal is to eliminate the B-cells that are producing the insulin receptor autoantibodies ^[1][10].

The standardized “NIH protocol” typically involves a combination of three types of medication:

• Rituximab: A targeted therapy that eliminates the specific immune cells (B-cells) making the antibodies ^[10][8].
• Cyclophosphamide: A medication that further helps suppress the overactive immune response ^[9].
• Dexamethasone: A potent steroid used to quickly reduce inflammation and immune activity ^[8].

As these treatments work to clear the antibodies from your system, your body’s sensitivity to insulin will begin to return.

The Challenge of “Switching” Symptoms

TBIRS is unique because of how the antibodies behave. While they usually block insulin (causing extreme high blood sugar), they can sometimes “switch” their behavior and begin to mimic insulin ^[4]. This can lead to hypoglycemia (dangerously low blood sugar), even if you haven’t taken insulin recently ^[11]. This volatility is why close monitoring by a specialist team is essential.

Explaining TBIRS to Family and Friends

Because TBIRS is so rare, friends and family might mistakenly assume you just have very severe Type 2 diabetes. They might suggest diet changes or express confusion over your treatment.

A simple way to explain it: “I don’t have typical diabetes. I have a rare autoimmune disease where my immune system is attacking the locks on my cells, so the insulin can’t get in. My treatment involves immune-suppressing medications to stop the attack, which is why I need specialized care.”

Moving Toward Remission

The ultimate goal of therapy is remission, defined as the point where these autoantibodies are no longer detectable in your blood ^[12]. When this happens, blood sugar levels often normalize, and many patients are eventually able to stop taking insulin entirely ^[1][13]. While the road to remission requires intensive treatment and patience, the transition from an “untreatable” condition to a curable one is one of the most significant advances in modern endocrinology ^[9].